Advanced Preclinical Models for Immunology, Oncology and Infectious Disease
News Sep 29, 2015
Human immune system engrafted mouse models are being applied in multiple disciplines from basic research into the human immune system, modeling of certain human-specific infectious diseases, efficacy testing of immunotherapy approaches, to safety assessment for large molecule therapeutics.
As part of European Biotech Week, Taconic Biosciences is hosting a series of symposia focusing on the latest applications for advanced preclinical mouse models.
The events are scheduled in Berlin on October 12th, Zürich October 14th, and Vienna October 16th. The objective of the series is to provide biomedical research professionals with knowledge and insight about how to generate and use better, more predictive models for improved translational outcomes.
Topic areas include:
• The super immune deficient CIEA NOG mouse® platform: a foundation for research in oncology, immunology and infectious disease
• How patient-derived xenograft (PDX) models can change the oncology drug discovery paradigm, including use of PDX models in personalized medicine to identify appropriate clinical trials for individual patients
• The latest advances in utilizing immune deficient mouse strains to reduce overall animal usage and save time and money
• Currently available human immune system engrafted mouse models, including use in combinations of human immune system and PDX applications
• The application of human immune system engrafted mice to infectious disease and autoimmune disease discovery
• How next generation human immune system engrafted mouse models will impact future research directions
Dr. Michael Seiler
Associate Director, Product Management - Taconic Biosciences
Dr. Seiler will discuss the current state of human immune system engrafted mouse models, including their recent application to immune-oncology drug efficacy testing. He will also cover cutting edge developments in next generation human immune system mice, including super immunodeficient NOG mice which have been further genetically modified to express particular human cytokines designed to promote engraftment or differentiation of certain human cell types.
• Dr. Jonas Nilsson, Sahlgrenska Cancer Center, University of Gothenberg (Berlin)
• Dr. Julia Schueler, Oncotest (Zürich)
• Dr. Patrick Nef, Transcure bioServices (Zürich)
• Dr. Els Hermans, KU Leuven (Zürich, Vienna)
• Dr. Yannick Romero, Transcure bioServices (Vienna)
• Dr. Megan MacBride, Taconic Biosciences (Berlin, Zürich, Vienna)
• Dr. Jean-Francois Mayol, Transcure bioServices (Berlin)